Biopharma Companies in France

Nicox is an international ophthalmic R&D company, based in Valbonne, France, dedicated to developing innovative therapeutics to help maintain vision and improve ocular health.

We focus on addressing significant unmet needs in glaucoma and ocular allergic conjunctivitis, with a leading program, NCX 470, successfully completing Phase 3 clinical development in the U.S. and China. Our portfolio also includes NCX 1728, a candidate under preclinical evaluation for retinal conditions.

Nicox leverages its proprietary nitric oxide donation research platform and strategic collaborations to advance its pipeline. We are proud to offer commercially available products, VYZULTA® for glaucoma and ZERVIATE® for ocular allergic conjunctivitis, with ZERVIATE also approved for use in China.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).

C4Diagnostics is a French-based biotech specialized in the development of in vitro diagnostic (IVD) tests for human infectious diseases C4Diagnostics' strategy for the better management of Human infectious diseases, is to develop game changing IVD tests which are significantly faster than standard methods whilst maintaining comparable or better performance. Its portfolio currently focuses on the diagnosis of Covid-19 (C4Covid-19), Legionnaires’ Disease (C4Legio LFA), urinary tract infections (C4UTI) and the development of antimicrobial susceptibility tests (C4AST). C4Diagnostics also has a business unit dedicated to environmental diagnostics, called C4Environment. It provides services for the detection of SARS-CoV-2 and other pathogens in the environment (wastewater, air, surface) and has contributed to several Covid-19 surveillance and prevention campaigns since the beginning of the pandemic. With its rapid and highly sensitive IVD tests, C4Diagnostics ambitions to become one of the main actors in the diagnosis of human infectious diseases field, by giving medical labs and healthcare professionals sensible and reliable diagnostic information in a timely manner. The game changing diagnostic solutions developed by C4Diagnostics are a leverage to fight against antibiotic resistance and curb infectious disease epidemics. contact@C4Diagnostics.com

CNRS UMR8199 is a French research institute based in Lille, specializing in the study of metabolic diseases and their genetic causes.

Our team, led by Pr. Philippe Froguel, focuses on understanding the molecular mechanisms behind diseases like diabetes and obesity, with the ultimate goal of developing more effective prevention and treatment strategies.

We conduct cutting-edge research in genomics and molecular physiology, contributing to a deeper understanding of these complex conditions and paving the way for personalized medicine. We are a key player in the **biotechnology research** sector, collaborating with leading institutions globally.

Established in 1995, CNRS UMR8199 has grown to a team of 11 researchers, furthering our commitment to advancing scientific knowledge and improving patient outcomes.

Orano Med is a French research and development company specializing in the production of high-purity lead-212 (Pb-212), a rare radioactive isotope, and driving innovation in targeted cancer therapies.

Based on a program initiated in 2005, Orano Med has pioneered the targeted alpha therapy (TAT) approach, recognizing and destroying cancer cells while minimizing harm to healthy tissue.

Leveraging Macrocyclics, Inc., a key component of Orano Med, the company operates a robust industrial platform for Pb-212 production and maintains a strong pipeline of research and development, including 18 clinical trials and over 30 patents.

With 220 employees across France and the United States, Orano Med is committed to advancing the field of nuclear medicine and improving patient outcomes through cutting-edge radiotherapeutic solutions.

Iktos is a Paris, France-based artificial intelligence company revolutionizing drug discovery.

We specialize in applying generative AI to medicinal chemistry, enabling pharmaceutical companies and research institutions to design and optimize molecules in silico. Our proprietary SaaS platforms, Makya™ and Spaya™, combined with our AI-driven robotics platform, dramatically accelerate the entire drug development process – from initial design to synthesis and testing.

Iktos is at the forefront of innovation, leveraging cutting-edge technology to reduce R&D timelines and increase the success rate of new drug candidates, particularly in oncology and autoimmune diseases. We are proud to have received significant investment and recognition, including a recent EIC Accelerator grant, demonstrating our commitment to transforming the future of drug discovery.